Chen‐Yen Lin

Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1

Philip J. Mease, Désirée van der Heijde, Masato Okada et al. · Annals of the Rheumatic Diseases · 2016 · 568 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Updated Prognostic Model for Predicting Overall Survival in First-Line Chemotherapy for Patients With Metastatic Castration-Resistant Prostate Cancer

Susan Halabi, Chen‐Yen Lin, William K. Kelly et al. · Journal of Clinical Oncology · 2014 · 475 citations

Medicine, Biostatistics, Oncology +17

Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)

Ohsang Kwon, Maryanne M. Senna, Rodney Sinclair et al. · American Journal of Clinical Dermatology · 2023 · 147 citations · Full text

Medicine, Dermatology, Pharmacology +13

Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis

Caitriona Ryan, Alan Menter, Lyn Guenther et al. · British Journal of Dermatology · 2018 · 119 citations · Full text

Medicine, Dermatology, Pharmacotherapy +13

Prostate-Specific Antigen Changes As Surrogate for Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Second-Line Chemotherapy

Susan Halabi, Andrew J. Armstrong, Oliver Sartor et al. · Journal of Clinical Oncology · 2013 · 104 citations · Full text

Medicine, Oncology, Pharmacology +16